Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris



Press release





  • The results presented demonstrate the capacity of molecular combing to characterize rearrangements formed as a result of CRISPR/Cas9-induced breaks and improve biosafety assessment of gene editing.



Bagneux (France), July 27, 2017 – Genomic Vision (FR0011799907 – GV), a company specialized in the development of diagnostic solutions for early cancer detection, genetic diseases and tools for life sciences research, today announced that the result of its collaboration with one of the leading genome editing companies has been presented during an oral presentation* at the 3rd Cold Spring Harbor Laboratory Meeting (CSHL) on Genome Engineering, held from July 21 to 23, 2017 in Cold Spring Harbor (NY).


In this collaboration, molecular combing was used to characterize the type and the frequency of DNA rearrangements formed as a result of CRISPR/Cas9-mediated gene editing on two disease loci. The results obtained with molecular combing complemented those provided by other approaches and contributed to a more comprehensive safety evaluation of the editing protocols.


Dr Lucia Cinque, Director of Product Innovation at Genomic Vision and co-author of the presentation, says: The results of this study further reinforce our belief in the value of molecular combing for the development of safe genome editing applications. This is particularly important for therapeutic use, where quantification of rearrangements coupled with a thorough characterization of the ensuing cellular response is critical. This fruitful collaboration has not only shown the potential of molecular combing to leading experts in the field; it has also enabled Genomic Vision to promptly initiate key product improvements in order to facilitate a more wide-spread adoption of its technology as one of the essential tools for the quality and safety control of advanced genome editors.”


*  Presentation Title:  “Characterization of genomic rearrangements in response to CRISPR/Cas9-induced double strand breaks”(



GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing the identification of genetic abnormalities, GENOMIC VISION supports the R&D productivity of pharmaceutical companies, leaders in the diagnostic industry and research labs.

The Company develops a strong portfolio of diagnostic tests (breast and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based in Bagneux, near Paris, the Company employs approximately 60 people. GENOMIC VISION is a public company listed on compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907). For further information, please visit



Genomic Vision

Aaron Bensimon

Co-fondateur et Président du Directoire

Tél. : +33 1 49 08 07 50


Press Relations

Bruno Arabian

Tel. : +33 1 83 62 34 84


Investor Relations

Dušan Orešanský / Emmanuel Huynh

Tel. : +33 1 44 71 94 92

Membre des indices CAC® Mid & Small et CAC® All-Tradable



This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.

Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the  “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision ( and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.


This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.